Clinical trial

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

NCT03386071

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Trametinib 2 mg Normalized identity: trametinib 2 MGView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Design: EXPANDED_ACCESS · Status: NO LONGER AVAILABLE · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNO_LONGER_AVAILABLE

Study typeEXPANDED_ACCESS

Start dateUnknown

PhaseN/A

Conditions

Progressive Metastatic Castrate Resistant Prostate Cancerunresolved

Interventions

Trametinib 2 mgDRUG · verified · RxNorm: trametinib 2 MG

Sponsors & collaborators

Jonsson Comprehensive Cancer Centerlead sponsor

Novartiscollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03386071 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.